Tags

Type your tag names separated by a space and hit enter

Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy.
Am J Clin Nutr. 2004 May; 79(5):765-73.AJ

Abstract

BACKGROUND

Dietary docosahexaenoic acid (DHA) has triacylglycerol-lowering potential and undergoes in vivo retroconversion to eicosapentaenoic acid (EPA) in humans. Hormone replacement therapy (HRT) influences circulating lipid concentrations and fatty acid metabolism. DHA supplementation has not been studied in postmenopausal women.

OBJECTIVE

We studied the effects of supplementation with DHA (free of EPA) on the resulting elevation in EPA and on selected cardiovascular disease risk factors in postmenopausal women.

DESIGN

Women receiving (n = 18) and not receiving (n = 14) HRT completed a randomized, double-blind, placebo-controlled crossover trial with a DHA supplement (2.8 g DHA/d). A washout period of > or =6 wk divided the two 28-d intervention periods. Fasting blood samples were collected for analysis.

RESULTS

In all women, DHA supplementation was associated with significant changes (P < 0.05), including 20% lower serum triacylglycerol concentrations, 8% higher HDL-cholesterol concentrations, a 28% lower overall ratio of serum triacylglycerol to HDL cholesterol, and a 7% decrease in resting heart rate. DHA supplementation resulted in a 45% lower net increase (P = 0.02) in EPA and a 42% lower (P = 0.0028) estimated percentage retroconversion of DHA to EPA [DeltaEPA/(DeltaEPA + DeltaDHA) x 100] in women receiving than in those not receiving HRT.

CONCLUSION

With DHA supplementation, the accumulation of EPA in serum phospholipids is significantly attenuated in postmenopausal women receiving HRT compared with that in women not receiving HRT. DHA supplementation can also favorably influence selected cardiovascular disease risk factors in postmenopausal women.

Authors+Show Affiliations

Department of Human Biology and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada N1G 2W1.No affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15113713

Citation

Stark, Ken D., and Bruce J. Holub. "Differential Eicosapentaenoic Acid Elevations and Altered Cardiovascular Disease Risk Factor Responses After Supplementation With Docosahexaenoic Acid in Postmenopausal Women Receiving and Not Receiving Hormone Replacement Therapy." The American Journal of Clinical Nutrition, vol. 79, no. 5, 2004, pp. 765-73.
Stark KD, Holub BJ. Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy. Am J Clin Nutr. 2004;79(5):765-73.
Stark, K. D., & Holub, B. J. (2004). Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy. The American Journal of Clinical Nutrition, 79(5), 765-73.
Stark KD, Holub BJ. Differential Eicosapentaenoic Acid Elevations and Altered Cardiovascular Disease Risk Factor Responses After Supplementation With Docosahexaenoic Acid in Postmenopausal Women Receiving and Not Receiving Hormone Replacement Therapy. Am J Clin Nutr. 2004;79(5):765-73. PubMed PMID: 15113713.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy. AU - Stark,Ken D, AU - Holub,Bruce J, PY - 2004/4/29/pubmed PY - 2004/5/27/medline PY - 2004/4/29/entrez SP - 765 EP - 73 JF - The American journal of clinical nutrition JO - Am J Clin Nutr VL - 79 IS - 5 N2 - BACKGROUND: Dietary docosahexaenoic acid (DHA) has triacylglycerol-lowering potential and undergoes in vivo retroconversion to eicosapentaenoic acid (EPA) in humans. Hormone replacement therapy (HRT) influences circulating lipid concentrations and fatty acid metabolism. DHA supplementation has not been studied in postmenopausal women. OBJECTIVE: We studied the effects of supplementation with DHA (free of EPA) on the resulting elevation in EPA and on selected cardiovascular disease risk factors in postmenopausal women. DESIGN: Women receiving (n = 18) and not receiving (n = 14) HRT completed a randomized, double-blind, placebo-controlled crossover trial with a DHA supplement (2.8 g DHA/d). A washout period of > or =6 wk divided the two 28-d intervention periods. Fasting blood samples were collected for analysis. RESULTS: In all women, DHA supplementation was associated with significant changes (P < 0.05), including 20% lower serum triacylglycerol concentrations, 8% higher HDL-cholesterol concentrations, a 28% lower overall ratio of serum triacylglycerol to HDL cholesterol, and a 7% decrease in resting heart rate. DHA supplementation resulted in a 45% lower net increase (P = 0.02) in EPA and a 42% lower (P = 0.0028) estimated percentage retroconversion of DHA to EPA [DeltaEPA/(DeltaEPA + DeltaDHA) x 100] in women receiving than in those not receiving HRT. CONCLUSION: With DHA supplementation, the accumulation of EPA in serum phospholipids is significantly attenuated in postmenopausal women receiving HRT compared with that in women not receiving HRT. DHA supplementation can also favorably influence selected cardiovascular disease risk factors in postmenopausal women. SN - 0002-9165 UR - https://www.unboundmedicine.com/medline/citation/15113713/Differential_eicosapentaenoic_acid_elevations_and_altered_cardiovascular_disease_risk_factor_responses_after_supplementation_with_docosahexaenoic_acid_in_postmenopausal_women_receiving_and_not_receiving_hormone_replacement_therapy_ L2 - https://academic.oup.com/ajcn/article-lookup/doi/10.1093/ajcn/79.5.765 DB - PRIME DP - Unbound Medicine ER -